Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
72.65
+1.45 (2.04%)
At close: Jun 3, 2026, 4:00 PM EDT
69.66
-2.99 (-4.12%)
After-hours: Jun 3, 2026, 7:40 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 730 employees as of December 31, 2025. The number of employees increased by 230 or 46.00% compared to the previous year.
Employees
730
Change (1Y)
230
Growth (1Y)
46.00%
Revenue / Employee
$1,053,556
Profits / Employee
$63,947
Market Cap
7.80B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 730 | 230 | 46.00% | 730 | 0 |
| Dec 31, 2024 | 500 | 148 | 42.05% | 500 | 0 |
| Dec 31, 2023 | 352 | 53 | 17.73% | 352 | 0 |
| Dec 31, 2022 | 299 | 61 | 25.63% | 299 | 0 |
| Dec 31, 2021 | 238 | 2 | 0.85% | 238 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| PTC Therapeutics | 991 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Immunovant | 315 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 253 |
CORT News
- 5 days ago - Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure - Business Wire
- 6 days ago - Corcept Therapeutics price target raised to $135 from $110 at Canaccord - TheFly
- 6 days ago - Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright - TheFly
- 7 days ago - Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant - TheFly
- 7 days ago - Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome - Business Wire
- 21 days ago - Corcept Therapeutics upgraded to Buy from Neutral at UBS - TheFly
- 21 days ago - Corcept Therapeutics upgraded to Buy from Neutral at UBS - TheFly
- 4 weeks ago - Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright - TheFly